Genetic polymorphisms of CYP17A1 in steroidogenesis pathway are associated with risk of progression to castration-resistant prostate cancer in Japanese men receiving androgen deprivation therapy

International Journal of Clinical Oncology

Volumn 18, Issue 4, 2013, Pages 711-717

  Yamada, Takeshi ^a   Nakayama, Masashi ^b,d   Shimizu, Tomohito ^a   Nonen, Shinpei ^a,c   Nakai, Yasutomo ^b   Nishimura, Kazuo ^d   Fujio, Yasushi ^a   Okuyama, Akihiko ^b   Azuma, Junichi ^a,c   Nonomura, Norio ^b  

^a OSAKA UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c HYOGO COLLEGE OF MEDICINE   (Japan)

^d OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

Author keywords

Androgen deprivation therapy; CYP17A1; Pharmacogenomics; Prostate cancer; SNPs

Indexed keywords

ANTIANDROGEN; CYTOCHROME P450 17; CYTOCHROME P450 17A1; GONADORELIN DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER GROWTH; CASTRATION; CASTRATION RESISTANT PROSTATE CANCER; CYP17A1 GENE; GENE ACTIVITY; GENE FUNCTION; GENETIC ANALYSIS; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; ONCOGENE; PATIENT CODING; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; STEROIDOGENESIS; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; DISEASE PROGRESSION; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RETROSPECTIVE STUDIES; STEROID 17-ALPHA-HYDROXYLASE; TREATMENT OUTCOME;

EID: 84882567571     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-012-0430-8     Document Type: Article

References (22)

1. Quinn M, Babb P (2002) Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part II: individual countries. BJU Int 90(2):174-184
2. Edwards J, Krishna NS, Grigor KM et al (2003) Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br J Cancer 89(3):552-556
3. Fujimoto N, Miyamoto H, Mizokami A et al (2007) Prostate cancer cells increase androgen sensitivity by increase in nuclear androgen receptor and androgen receptor coactivators; a possible mechanism of hormone-resistance of prostate cancer cells. Cancer Invest 25(1):32-37
4. Arnold JT, Le H, McFann KK et al (2005) Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells. Am J Physiol Endocrinol Metab, 288(3):E573-584
5. Shah S, Small E (2010) Emerging biological observations in prostate cancer. Expert Rev Anticancer Ther 10(1):89-101
6. D'Amico F, Biancolella M, Margiotti K et al (2007) Genomic biomarkers, androgen pathway and prostate cancer. Pharmacogenomics 8(6):645-661
7. Ross RW, Oh WK, Xie W et al (2008) Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer. J Clin Oncol 26(6):842-847
8. Singh AS, Chau CH, Price DK et al (2005) Mechanisms of disease: polymorphisms of androgen regulatory genes in the development of prostate cancer. Nat Clin Pract Urol 2(2):101-107
9. Torkko KC, van Bokhoven A, Mai P et al (2008) VDR and SRD5A2 polymorphisms combine to increase risk for prostate cancer in both non-Hispanic White and Hispanic White men. Clin Cancer Res 14(10):3223-3229
10. Maeda O, Usami M (2005) Summary of General rules for clinical and pathological studies on prostate cancer (3rd edition). Nihon Rinsho 63(2):201-206
11. Akaza H (2006) Trends in primary androgen depletion therapy for patients with localized and locally advanced prostate cancer: Japanese perspective. Cancer Sci 4:243-247
12. De Coster R, Wouters W, Bruynseels J (1996) P450-dependent enzymes as targets for prostate cancer therapy. J Steroid Biochem Mol Biol, 56(1-6 Spec No):133-143
13. Attard G, Reid AH, A'Hern R et al (2009) Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 27(23):3742-3748
14. de Bono JS, Logothetis CJ, Molina A et al (2011) Abiraterone and increased survival in metastatic prostate cancer. New Engl J Med 364(21):1995-2005
15. Reid AH, Attard G, Danila DC et al (2010) Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol 28(9):1489-1495
16. Antognelli C, Mearini L, Talesa VN et al (2005) Association of CYP17, GSTP1, and PON1 polymorphisms with the risk of prostate cancer. Prostate 63(3):240-251
17. Mononen N, Seppala EH, Duggal P et al (2006) Profiling genetic variation along the androgen biosynthesis and metabolism pathways implicates several single nucleotide polymorphisms and their combinations as prostate cancer risk factors. Cancer Res 66(2):743-747
18. Habuchi T, Liqing Z, Suzuki T et al (2000) Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect. Cancer Res 60(20):5710-5713
19. Kakinuma H, Tsuchiya N, Habuchi T et al (2004) Serum sex steroid hormone levels and polymorphisms of CYP17 and SRD5A2: implication for prostate cancer risk. Prostate Cancer Prostatic Dis 7(4):333-337
20. Peduzzi P, Concato J, Kemper E et al (1996) A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol 49(12):1373-1379
21. Benjamini Y. Hochberg Y. (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Statist Soc ser B, 57(1): 298-300
22. Attard G, Reid AH, Yap TA et al (2008) Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol, 26(28):4563-4571